-
公开(公告)号：US10821110B2
公开(公告)日：2020-11-03
申请号：US15511955
申请日：2015-10-16
发明人： Jin Yang , Jin Woong Kim , Han Kyu Lee , Jae Hyun Kim , Chang Mo Son , Kyu Hwan Lee , Hyung-Ho Choi , Daehoon Kim , Tae-Young Ha , Jaekeol Rhee
IPC分类号： A61K31/506 , A61K9/00 , A61K9/14 , A61K9/20 , A61K9/48 , A61K31/132 , A61K31/357 , A61K31/40 , A61K31/4035 , A61K31/44 , A61K31/445 , A61K31/454 , A61K31/47 , A61K31/495 , A61K31/496 , A61K45/06 , C07C59/72 , C07D207/06 , C07D209/44 , C07D211/14 , C07D211/70 , C07D215/06 , C07D295/096 , C07D317/72 , C07D401/04 , C07D403/04 , C07D413/04 , C07D417/04 , A61K31/192
摘要： The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (DPPIV) inhibitor-based, sulfonylurea-based, thiazolidinedione (TZD)-based, biguanide-based, and sodium/glucose cotransporter 2 (SGLT2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type I, diabetes type II, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X.
-
公开(公告)号：US09758527B2
公开(公告)日：2017-09-12
申请号：US15307719
申请日：2015-05-01
发明人： Jin Yang , Jinwoong Kim , Han Kyu Lee , Jae Hyun Kim , Chang Mo Son , Kyu Hwan Lee , Jeongun Hwang , Hyung-Ho Choi , Daehoon Kim , Jaekeol Rhee
IPC分类号： C07D491/113 , C07D211/22 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/14 , C07D487/10
CPC分类号： C07D491/113 , C07D211/22 , C07D211/46 , C07D211/58 , C07D211/62 , C07D211/72 , C07D211/74 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D413/04 , C07D413/14 , C07D417/12 , C07D487/10
摘要： The present invention relates to: a cyclohexene derivative; a preparation method therefor; and a pharmaceutical composition for preventing or treating metabolic diseases, containing the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.
-
搜索结果
2 条记录 (耗时 0.015 秒)
